

Dear << Test First Name >>,

We hope you all had a successful and insightful 52nd Union conference! We were especially pleased to see a dedicated track for Modelling, something we have been advocating for a long time. As always, the TB Modelling and Analysis Consortium ([TB MAC](#)) newsletter is filled with information for TB modellers, epidemiologists, and decision-makers, please enjoy!


### **Benchmarks, reporting, and review approach out now**

A detailed description and analysis of our efforts to create a benchmarking, reporting and review approach to improve the quality and transparency of country-level TB modelling to inform decision-making is out now in IJTLD, available [here](#). The editors describe it as

"an important step forward to increase rigour, which will, in turn, promote broader acceptance and trust in modelling to inform policy" - [Campbell et al, 2021](#)

### **Better data = better resource allocation**

In our recent letter, available [here](#), we argue that data on the resource needs of TB intervention activities for active case finding are available, but likely underestimate the actual resources required to implement interventions, making efficient and effective resource allocation for TB a challenge.



### **Brand new case studies**

In conjunction with researchers in the field, we have produced a number of case-studies of the experiences of modellers working with decision-makers at both country and global levels. These can be found in full [here](#), and include:

- [A cost assessment for preventative treatment](#) (published in [Clinical Infectious Diseases](#))

- [An assessment of the impact of primary health care on TB in Brazil](#) (available as a [pre-print](#))
- [A parameterisation of the kinetics of early TB disease](#)
- [A cost-effectiveness analysis of Xpert on stool to diagnose TB in children in Ethiopia and Indonesia](#)

These pieces provide great insight into how modelling can be used and communicated to support decision making.

### Recent publications from our community

[Dye](#) [Book Chapter] Chapter 5 considers prevention in public health, with particular reference to TB modelling.

[Richards et al](#) [Pre-print] review TB natural history literature to quantify progression and regression between three states of pulmonary TB disease

[Choo et al](#) model TB control strategies in South Korea

[Arinaminpathy et al](#) estimate the cost-effectiveness of engaging with the private healthcare sector in India

[Yu et al](#) model the future incidence of TB in Shanghai, China

[Goscé et al](#) describe the country-level modelling tool Optima TB, and its application in Belarus

[Uppal et al](#) review modelling and economic evidence for TB preventive treatment in people living with HIV

[Jo et al](#) estimate the cost-effectiveness of a case-finding strategy in Zambia

[Zhang et al](#) model TB disease progression as a dynamic shift in bacterial concentration

[You et al](#) describe a protocol for modelling the cost-effectiveness of China's primary healthcare model

[Ilaiwy and Dowdy](#) estimate the cost-effectiveness of 3HP relative to INH-9 in Syrian refugees

[Otoo et al](#) model drug resistance and leaky vaccination

[Estill et al](#) estimate the future burden of disease and return on investment in four countries of the Western Pacific Region

[Pečerska et al](#) quantify the transmission fitness costs of drug resistance

[Cicchese et al](#) model drug-therapy factors to design combination therapies

[Millar et al](#) model the reduced responsiveness of T cells within lung granulomas in terms of cytokine production

[Wong et al](#) investigate the role of IL-10 in *M.tb* infection

[Tanvi et al](#) model HIV-TB co-infection in the presence of reinfection and recurrence

[Shaweno et al](#) model the impact and cost-effectiveness of a hotspot-targeted active case finding strategy in Ethiopia

[Shrestha et al](#) model the impact of community-wide screening and treatment with preventive therapy for latent TB infection in a mid-sized city in India

If you have any recently published TB modelling papers that you would like us to highlight in our future newsletters, [email](#) us with details.

For more information on TB MAC, or to get involved, please contact any of the [TB MAC Committee](#), visit [www.tb-mac.org](http://www.tb-mac.org) or email us directly at [tb-mac@lshtm.ac.uk](mailto:tb-mac@lshtm.ac.uk).

On behalf of all of us here at TB MAC we thank you for your ongoing subscription and wish you a happy festive season and new year.

Best wishes,

Richard, Finn, Madeleine and the TB MAC Committee

[www.tb-mac.org](http://www.tb-mac.org)

[tb-mac@lshtm.ac.uk](mailto:tb-mac@lshtm.ac.uk)

### GDPR compliance

In line with the new European data protection regulations (GDPR), we would like to make sure that you still want to hear from us and keep receiving the newsletter. Subscription to the newsletter means we have your name, email and organisation details stored in a private mailing list. If you no longer like us to keep this information or no longer wish to receive newsletters please click on unsubscribe below. Should you choose not to unsubscribe we will take this as your acceptance to continue receiving newsletters from us.



Tweet



Forward

*Copyright © 2021 TB Modelling and Analysis Consortium, All rights reserved.*

[unsubscribe from this list](#) [update subscription preferences](#)

